Table 1.
Baseline characteristics of participants
| Characteristic | Total (N = 31) |
|---|---|
| Age at heart transplant, y | 47.6 (33.0–60.9) |
| Female | 10 (32.3) |
| Race | |
| Caucasian | 16 (51.6) |
| Black | 5 (16.1) |
| Asian | 7 (22.6) |
| Mixed | 3 (9.7) |
| Indication for cardiac transplant | |
| Nonischemic | 16 (51.6) |
| Ischemic | 6 (19.4) |
| Hypertrophic | 5 (16.1) |
| Congenital | 1 (3.2) |
| Other | 3 (9.7) |
| Bridged with durable LVAD | 10 (32.3) |
| Bridged with CMAG or ECMO | 4 (12.9) |
| Medical history after transplant | |
| Hypertension | 17 (54.8) |
| Diabetes | 14 (45.2) |
| Chronic kidney disease | 10 (32.3) |
| Graft function | |
| Pacemaker | 6 (20.0) |
| History of primary graft dysfunction | 3 (10.0) |
| Cardiac allograft vasculopathy | 9 (32.1) |
| Acute cellular rejection at 1 year | 16 (53.3) |
| Treated antibody-mediated rejection | 2 (6.7) |
| Persistent donor-specific antibody | 7 (23.3) |
| History of graft impairment (LVEF < 50%) | 4 (12.9) |
| LVEF, % | 61.0 (57.0–65.0) |
| Complications after transplant | |
| Cancer | 3 (10.0) |
| Treated CMV | 5 (16.7) |
| Immunosuppression | |
| Prednisone | 26 (83.9) |
| Tacrolimus | 23 (74.2) |
| Cyclosporine | 5 (16.1) |
| Mycophenolic acid | 24 (77.4) |
| Sirolimus | 10 (32.3) |
Data are presented as median (interquartile range) and count (percentage) for continuous and categorical data, respectively. Graft dysfunction was defined as any history of decline in LVEF of 15% or more from baseline.
CMAG, CentriMag biventricular assist device; CMV, cytomegalovirus; ECMO, extracorporeal membrane oxygenation; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction.